+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antidepressant Drugs Market 2019-2025

  • ID: 5129624
  • Report
  • May 2020
  • Region: Global
  • Orion Market Research Private Limited
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Alkermes Plc
  • AstraZeneca Plc
  • Eli Lilly & Co.
  • H. Lundbeck A/S
  • Mylan N.V.
  • Pfizer Inc.
  • MORE
Global Antidepressant Drugs Market Size, Share & Trends Analysis Report by Depressive Disorder (Major Depressive Disorder (MDD), Obsessive-compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD), Panic Disorder (PD), and Other Depressive Disorders), By Drug Class (Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants, Monoamine Oxidase Inhibitors (MAOIs), and Other Medications) Forecast, 2019-2025.

The global antidepressant drug market is estimated to grow significantly during the forecast period. The primary factors that drive the growth of the market include increased prevalence of depression, rising geriatric population along with the advent of novel drugs with minimum side effects associated. Further, increasing stress levels among the peoples and elevated alcohol consumption and smoking also lead to this disorder which may encourage the adoption of antidepressant drugs and drive the market growth during the forecast period. However, lack of awareness along with the unavailability of the drugs in the undeveloped economies is expected to hamper the growth of the market during the forecast period.

The global antidepressant drugs market is segmented on the basis of depressive disorder and drug class. Based on the depressive disorder, the market is segmented into major depressive disorder (MDD), obsessive-compulsive disorder (OCD), generalized anxiety disorder (GAD), panic disorder (PD), and other depressive disorders. MDD is likely to hold a significant share in the market. Based on the drug class, the market is segmented as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants, monoamine oxidase inhibitors (MAOIs), and other medications. SNRIs segment is projected to hold a significant share in the market.

Geographically, the study of the global antidepressant drugs market report covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), and the Rest of the World. Asia-Pacific is estimated to exhibit a significant growth rate in the global market during the forecast period. The increasing geriatric population in the region drives the growth of the market. In addition, improving healthcare infrastructure further gives a boost to the regional growth of the market.

Moreover, the study of the global antidepressant drugs market report covers the analysis of various players operating in the market. Some of the key players covered in the report include Pfizer Inc., Eli Lilly & Co., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services Inc., Merck & Co., Inc., Novartis International AG, Sanofi S.A., Bristol Myers Squibb Co., Intellipharmaceutics International Inc., and GlaxoSmithKline Plc.

Research Methodology

The market study of the global antidepressant drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary sources include:
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for pharmaceutical companies, drug manufacturers, contract manufacturers, industry associations and experts, research organizations, academic institutes, government organizations, regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. Global Antidepressant Drugs Market Research and Analysis by Depressive Disorder
2. Global Antidepressant Drugs Market Research and Analysis by Drug Class

The Report covers:
  • Comprehensive research methodology of the global antidepressant drug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global antidepressant drugs market.
  • Insights about market determinants which are stimulating the global antidepressant drugs market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of the market players.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Alkermes Plc
  • AstraZeneca Plc
  • Eli Lilly & Co.
  • H. Lundbeck A/S
  • Mylan N.V.
  • Pfizer Inc.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. Global Antidepressant Drugs Market by Depressive Disorder
5.1.1. Major Depressive Disorder (MDD)
5.1.2. Obsessive-compulsive Disorder (OCD)
5.1.3. Generalized Anxiety Disorder (GAD)
5.1.4. Panic Disorder (PD)
5.1.5. Other Depressive Disorders
5.2. Global Antidepressant Drugs Market by Drug Class
5.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
5.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
5.2.3. Tricyclic Antidepressants (TCA)
5.2.4. Monoamine Oxidase Inhibitors (MAOIs)
5.2.5. Other Medications (Atypical Antidepressants)

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles
7.1. Alkermes Plc
7.2. Allergan PLC
7.3. Breckenridge Pharmaceutical, Inc.
7.4. AstraZeneca Plc
7.5. Bristol Myers Squibb Co.
7.6. Camber Pharmaceutical Inc.
7.7. Eli Lilly & Co.
7.8. GlaxoSmithKline Plc
7.9. H. Lundbeck A/S
7.10. Intellipharmaceutics International Inc.
7.11. Johnson & Johnson Services Inc.
7.12. Merck & Co., Inc.
7.13. Mylan N.V.
7.14. Novartis International AG
7.15. Pfizer Inc.
7.16. Sanofi S.A.
7.17. Sun Pharmaceuticals Ltd.
7.18. Takeda Pharmaceutical Co.
7.19. Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
3 of 3
  • Alkermes Plc
  • Allergan PLC
  • Breckenridge Pharmaceutical, Inc.
  • AstraZeneca Plc
  • Bristol Myers Squibb Co.
  • Camber Pharmaceutical Inc.
  • Eli Lilly & Co.
  • GlaxoSmithKline Plc
  • H. Lundbeck A/S
  • Intellipharmaceutics International Inc.
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceuticals Ltd.
  • Takeda Pharmaceutical Co.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll